Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: selegiline hydrochloride

« Back to Dashboard

Summary for Generic Name: selegiline hydrochloride

Drug Master File Entries: see list15
Suppliers: see list2
Therapeutic Class:Antiparkinson Agents

Pharmacology for Ingredient: selegiline hydrochloride

Clinical Trials for: selegiline hydrochloride

Evaluation of Adhesion and Dermal Tolerability of EMSAM
Status: Completed Condition: Healthy

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
Status: Completed Condition: Healthy

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Status: Completed Condition: Major Depressive Disorder

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

A Pilot Study Assessing EmSam in Bipolar Depression
Status: Terminated Condition: Bipolar Depression

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Status: Completed Condition: Cognitive Disorders; HIV Infections

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Status: Completed Condition: Parkinson's Disease

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
Status: Completed Condition: Alzheimer Disease, Healthy Volunteer

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Status: Completed Condition: Marijuana Abuse

Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes
Status: Enrolling by invitation Condition: Type 1 Diabetes Mellitus; Exercise; Hypoglycemia; Carbohydrate Metabolism

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dava Pharms Inc
selegiline hydrochloride
TABLET;ORAL074641Aug 2, 1996DISCNNo<disabled><disabled>
Dava Pharms Inc
selegiline hydrochloride
CAPSULE;ORAL075352Nov 30, 1998RXNo<disabled><disabled>
selegiline hydrochloride
CAPSULE;ORAL020647May 15, 1996RXYes<disabled><disabled>
Apotex Inc
selegiline hydrochloride
TABLET;ORAL074871Jun 6, 1997RXYes<disabled><disabled>
Valeant Pharm Intl
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479Jun 14, 2006RXYes5,648,093<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn